Phase III, Randomized, Multicenter Double-Blind, Double Dummy Study to Evaluate the Efficacy and Safety of Etrolizumab Compared With Infliximab in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 May 2019
Price : $35 *
At a glance
- Drugs Etrolizumab (Primary) ; Infliximab
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms GARDENIA
- Sponsors Roche
- 07 May 2019 Planned End Date changed from 30 Sep 2020 to 21 Jul 2020.
- 07 May 2019 Planned primary completion date changed from 30 Jun 2020 to 28 Apr 2020.
- 07 May 2019 Status changed from recruiting to active, no longer recruiting.